• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Expert Q&A: Pharmacist-Led Strategies to Improve Cholesterol Management

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Amanda Gronniger, PharmD, CPh, BCCP discusses practical strategies pharmacists can use to improve cholesterol management, from lifestyle counseling to emerging therapies. Read More

Camber Pharmaceuticals Announces Addition of Olmesartan Medoxomil Tablets, USP

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Imdelltra Shows Survival Benefit in Small Cell Lung Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC. Read More

Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer

by MM360 Staff | Jun 3, 2025 | Uncategorized

Source: CureToday articles Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer. Read More

From MGUS to Myeloma: Understanding and Interrupting Disease Progression

by MM360 Staff | Jun 3, 2025 | Myeloma News

Source: Pharmacy Times articles The 2025 ASCO Annual Meeting discusses the latest advancements in understanding and treating precursor diseases. Read More
« Older Entries
Next Entries »

Recent Content

  • Canada agency backs coverage of new ovarian cancer drug
  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Cero seeking more safety, dosing data on T-cell therapy for AML
  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT